Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

MRP1 cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (8) ATP-binding cassette (ABC) transporters (2) Bacterial (1) BCRP (3) c-Met/HGFR (1) Calcium Channel (3) Caspase (2) Cholecystokinin Receptor (2) Drug Derivative (2) Endogenous Metabolite (1) Epigenetic Reader Domain (1) Fungal (1) HCV (1) HSP (1) Isotope-Labeled Compounds (4) Leukotriene Receptor (4) LPL Receptor (1) NF-κB (2) OAT (1) P-glycoprotein (19) PARP (1) Reference Standards (2) STAT (1) TNF Receptor (1) Topoisomerase (1)
By Research Areas:	Cancer (24) Endocrinology (2) Infection (2) Inflammation/Immunology (2) Metabolic Disease (3) Neurological Disease (2)

By Targets:

Antibiotic (1)

Apoptosis (8)

ATP-binding cassette (ABC) transporters (2)

Bacterial (1)

BCRP (3)

c-Met/HGFR (1)

Calcium Channel (3)

Caspase (2)

Cholecystokinin Receptor (2)

Drug Derivative (2)

Endogenous Metabolite (1)

Epigenetic Reader Domain (1)

Fungal (1)

HCV (1)

HSP (1)

Isotope-Labeled Compounds (4)

Leukotriene Receptor (4)

LPL Receptor (1)

NF-κB (2)

OAT (1)

P-glycoprotein (19)

PARP (1)

Reference Standards (2)

STAT (1)

TNF Receptor (1)

Topoisomerase (1)

By Research Areas:

Cancer (24)

Endocrinology (2)

Infection (2)

Inflammation/Immunology (2)

Metabolic Disease (3)

Neurological Disease (2)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) TREM receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19989A

MK-571 sodium Maximum Cited Publications 33 Publications Verification L-660711 sodium	P-glycoprotein LPL Receptor Leukotriene Receptor	Inflammation/Immunology
MK-571 (L-660711) sodium is an orally active, potent and selective competitive leukotriene D₄ (LTD₄) receptor antagonist, with K_i values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 sodium is also a inhibitor of multidrug resistance-associated protein MRP4 (ABCC4) and ABCC1 (MRP1). MK-571 sodium inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release .

HY-135336A

(S)-Verapamil hydrochloride (S)-(-)-Verapamil hydrochloride	P-glycoprotein Leukotriene Receptor Calcium Channel Apoptosis	Cancer
(S)-Verapamil hydrochloride (S(-)-Verapamil hydrochloride) inhibits leukotriene C4 (LTC4) and calcein transport by MRP1. (S)-Verapamil hydrochloride leads to the death of potentially resistant tumor cells .

HY-14942A

Berubicin hydrochloride RTA 744; WP 744; WP 769 hydrochloride	NF-κB Apoptosis Caspase Drug Derivative	Neurological Disease Cancer
Berubicin (RTA 744) hydrochloride is a Doxorubicin (HY-15142A) analog that can cross the blood-brain barrier. Berubicin hydrochloride inhibits P-gp and MRP1-mediated efflux and suppresses glioblastoma multiforme (GBM). Berubicin hydrochloride exerts toxic effects on leukemia cells by activating nuclear factor κB (NF-κB) and induces apoptosis in neuroblastoma cells. Berubicin hydrochloride can be used in the study of tumors related to the nervous system .

HY-17013

Dofequidar 2 Publications Verification MS-209 free base	P-glycoprotein	Cancer
Dofequidar (MS-209 free base) is an orally active quinoline compoundthat blocks P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MDR-1). Dofequidar has highly potent reversing effect on multidrug-resistant tumor cells. Dofequidar competitively inhibits ABCB1/P-gp, ABCC1/MRP-1, blocks the efflux of chemotherapeutic agents, increases the drug concentration in cancer cells, and enhances the chemotherapeutic effect .

HY-13574A

Biricodar 1 Publications Verification VX-710	P-glycoprotein	Cancer
Biricodar (VX-710) is a modulator of P-glycoprotein and *MRP-1; shows effective chemosensitizing activity in multidrug resistant cells*.

HY-128878

Dexloxiglumide	Cholecystokinin Receptor P-glycoprotein	Metabolic Disease Endocrinology
Dexloxiglumide is an orally active and selective cholecystokinin type A (CCKA) receptor antagonist. Dexloxiglumide is the active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8). Dexloxiglumide exhibits moderate Caco-2 permeability that is polarized, concentration dependent, and pH dependent. Dexloxiglumide increases *MRP1*-substrate fluorescein uptake. Dexloxiglumide can be studied in research for gastrointestinal diseases and tumors .

HY-W010649

Isoxazole	HSP Epigenetic Reader Domain ATP-binding cassette (ABC) transporters Bacterial Fungal Antibiotic	Infection Metabolic Disease Inflammation/Immunology Cancer
Isoxazole is a member of the five-membered heterocycle drug scaffold. Isoxazole has been used as a BET bromodomain inhibitor and can improve β-cell function in a diabetic mouse model. Isoxazole and its derivatives exhibit broad biological activities (such as antimicrobial, antibacterial, antifungal, antiviral, anticancer, anti-inflammatory, immunomodulatory, analgesic, anti-tuberculosis, and anti-diabetic effects). For example, the bicyclic Isoxazole can act as an HSP90 inhibitor, and the tricyclic Isoxazole is promising as a selective multidrug resistance protein (MRP1) inhibitor .

HY-N0248

Saikosaponin B2 2 Publications Verification	HCV P-glycoprotein	Infection Cancer
Saikosaponin B2 is an antiviral and anticancer agent that regulates multiple transporters (such as various solute carriers and ATP-binding cassette transporters including MRP1, MRP2, and OCT2). Saikosaponin B2 is isolated from the plant glycoside component of the roots of Bupleurum scorzonerifolium. Saikosaponin B2 enhances the liver targeting of anticancer drugs via vinegar-baked Radix Bupleuri. Saikosaponin B2 inhibits HCV entry, replication, and translation, is effective against Daclatasvir (HY-10466)-resistant strains, and exerts a synergistic effect when used in combination with Daclatasvir. Saikosaponin B2 is commonly used in studies related to hepatocellular carcinoma and HCV infection .

HY-162753

ZW-1226	P-glycoprotein	Cancer
ZW-1226 is a dual Tyrosyl DNA phosphodiesterase 2 (TDP2) and Multidrug resistance-associated protein 1 (MRP1) inhibitor with IC₅₀ values of 0.2 and 0.5 μM, respectively. ZW-1226 exhibits selectivity over other ABC transporters. ZW-1226 elevates intracellular GSH levels, and reverses *MRP1*-mediated drug resistance. ZW-1226 can be used for the research of leukemia, non-small-cell lung cancer, and multidrug resistant small-cell lung cancer .

HY-17013A

Dofequidar fumarate 2 Publications Verification MS-209	P-glycoprotein	Cancer
Dofequidar fumarate (MS-209) is an orally active quinoline compoundthat blocks P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MDR-1). Dofequidar fumarate has highly potent reversing effect on multidrug-resistant tumor cells. Dofequidar fumarate competitively inhibits ABCB1/P-gp, ABCC1/MRP-1, blocks the efflux of chemotherapeutic agents, increases the drug concentration in cancer cells, and enhances the chemotherapeutic effect .

HY-N7755

Estradiol 3-glucuronide sodium	Endogenous Metabolite ATP-binding cassette (ABC) transporters OAT	Others
Estradiol 3-glucuronide sodium is an estrogen metabolite, which is a glucuronide conjugate formed by the catalysis of uridine diphosphate glucuronosyltransferase in tissues such as the liver from Estradiol (HY-B0141). Estradiol 3-glucuronide sodium is a potent substrate of Mrp2, with an S₅₀ of 55.7 μM. Estradiol 3-glucuronide sodium achieves hepatobiliary transport in hepatocytes through basolateral uptake via OATP1B1, OATP1B3 and OATP2B1, as well as apical efflux via MRP2 and BCRP .

HY-14942

Berubicin RTA 744 free base; WP 744 free base; WP 769	NF-κB Apoptosis Caspase Drug Derivative	Neurological Disease Cancer
Berubicin (RTA 744 free base) is a Doxorubicin (HY-15142A) analog that can cross the blood-brain barrier. Berubicin inhibits P-gp and MRP1-mediated efflux and suppresses glioblastoma multiforme (GBM). Berubicin exerts toxic effects on leukemia cells by activating nuclear factor κB (NF-κB) and induces apoptosis in neuroblastoma cells. Berubicin can be used in the study of tumors related to the nervous system .

HY-17648

MBL-II-141	BCRP	Cancer
MBL-II-141 is potent ABCG2 inhibitor with an IC₅₀ of 0.11 μM. MBL-II-141 inhibits the transport function of ABCG2 in a non-competitive manner, preventing ABCG2 from pumping substrates (such as Irinotecan (HY-16562)) out of the cells, thereby increasing the accumulation of drugs within the cells. MBL-II-141 has no effect on ABCB1 (P-gp) and ABCC1 (MRP1) and has extremely low cytotoxicity (IG₅₀ > 100 μM). MBL-II-141 can be used for the study of multidrug resistance (MDR) cancers .

HY-164683

MRP1-IN-1	P-glycoprotein	Cancer
MRP1-IN-1 (Compound 9h) is a *MRP1* inhibitor with an EC₅₀ of 0.90 μM in HeLa-T5 cells .

HY-135336S

(R)-Verapamil-d7 (hydrochloride) (R)-(+)-Verapamil-d₇ (hydrochloride)	P-glycoprotein Isotope-Labeled Compounds Apoptosis	Cancer
(R)-Verapamil-d₇ (hydrochloride) is a deuterium labeled (R)-Verapamil hydrochloride. (R)-Verapamil hydrochloride ((R)-(+)-Verapamil hydrochloride) is a P-Glycoprotein inhibitor. (R)-Verapamil hydrochloride blocks MRP1 mediated transport, resulting in chemosensitization of MRP1-overexpressing cells to anticancer agents .

HY-W702292

(R)-(+)-Verapamil-d6 hydrochloride	Isotope-Labeled Compounds Apoptosis P-glycoprotein	Cancer
(R)-(+)-Verapamil-d₆ (hydrochloride) is deuterium labeled (R)-Verapamil (hydrochloride). (R)-Verapamil hydrochloride ((R)-(+)-Verapamil hydrochloride) is a P-Glycoprotein inhibitor. (R)-Verapamil hydrochloride blocks MRP1 mediated transport, resulting in chemosensitization of MRP1-overexpressing cells to anticancer agents .

HY-13574

Biricodar dicitrate VX 710-3	P-glycoprotein	Cancer
Biricodar dicitrate (VX 710-3) is the dicitrate salt form of Biricodar (HY-13574A). Biricodar dicitrate is an inhibitor for P-glycoprotein and multidrug resistance-associated protein 1 (MRP-1), which increases the accumulation of chemotherapy drugs within cancer cells and shows effective chemosensitizing activity in multidrug resistant cells .

HY-135336AS

(S)-Verapamil-d7 (hydrochloride) (S)-(-)-Verapamil-d₇ (hydrochloride)	Isotope-Labeled Compounds Leukotriene Receptor Calcium Channel Apoptosis	Cancer
(S)-Verapamil-d₇ (hydrochloride) is a deuterium labeled (S)-Verapamil hydrochloride. (S)-Verapamil hydrochloride (S(-)-Verapamil hydrochloride) inhibits leukotriene C4 (LTC4) and calcein transport by MRP1. (S)-Verapamil hydrochloride leads to the death of potentially resistant tumor cells .

HY-135336AS1

(S)-Verapamil-d6 (hydrochloride) (S)-(-)-Verapamil-d₆ (hydrochloride)	Isotope-Labeled Compounds Apoptosis Leukotriene Receptor Calcium Channel	Cancer
(S)-Verapamil-d₆ ((S)-(-)-Verapamil-d₆) hydrochloride is the deuterium labeled (S)-Verapamil hydrochloride. (S)-Verapamil hydrochloride (S(-)-Verapamil hydrochloride) inhibits leukotriene C4 (LTC4) and calcein transport by MRP1. (S)-Verapamil hydrochloride leads to the death of potentially resistant tumor cells .

HY-168711

P-gp inhibitor 27	P-glycoprotein	Cancer
P-gp inhibitor 27 (Compound D2) is an inhibitor for P-glycoprotein (P-gp), that downregulates the expression of P-gp and MRP1, increases the Rh123 accumulation in A2780/T cell, and reverses multidrug resistance to Paclitaxel (HY-B0015) (EC₅₀ is 88 nM) and Cisplatin (HY-17394) .

HY-161353

c-Met-IN-23	P-glycoprotein c-Met/HGFR	Cancer
c-Met-IN-23 (Compound 12g) is a c-Met inhibitor (IC₅₀ = 0.052 μM for c-Met). c-Met-IN-23 also inhibits MDR1 and MRP1/2 pumps in the cancerous HepG2 and BxPC3 cells. c-Met-IN-23 is an anticancer agent .

HY-128878R

Dexloxiglumide (Standard)	Cholecystokinin Receptor P-glycoprotein Reference Standards	Metabolic Disease Endocrinology
Dexloxiglumide (Standard) is the analytical standard of Dexloxiglumide. This product is intended for research and analytical applications. Dexloxiglumide is an orally active and selective cholecystokinin type A (CCKA) receptor antagonist. Dexloxiglumide is the active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8). Dexloxiglumide exhibits moderate Caco-2 permeability that is polarized, concentration dependent, and pH dependent. Dexloxiglumide increases *MRP1*-substrate fluorescein uptake. Dexloxiglumide can be studied in research for gastrointestinal diseases and tumors .

HY-179683

MRP1-IN-2	P-glycoprotein	Cancer
MRP1-IN-2 (Compound 21) is a selective *MRP1* inhibitor with a relatively weak inhibitory effect on P-gp. MRP1-IN-2 exhibits a strong accumulation effect of calcein, with its EC₅₀ value being 177 nM. MRP1-IN-2 enhances the activity of Doxorubicin (HY-15142A) on drug-resistant cells. MRP1-IN-2 can be used for the study of multidrug-resistant cancers .

HY-118083

Pentamethoxymorin MRS923	BCRP	Cancer
Pentamethoxymorin (MRS923) is a selective breast cancer resistance protein (BCRP/ABCG2) inhibitor. Pentamethoxymorin shows selectivity for BCRP over P-gp and MRP1. Pentamethoxymorin inhibits MDCK BCRP cells with IC₅₀ vaues of 5.98 μM and 5.94 μM in Hoechst 33342 (HY-15559) assay and Pheophorbide A (HY-125665) assay, respectively. Pentamethoxymorin can be used for the study of ccancer .

HY-183143

Lss-11	Topoisomerase Apoptosis TNF Receptor PARP STAT P-glycoprotein	Cancer
Lss-11 is a topoisomerase inhibitor. LSS-11 enhances cell death in cancer cells by inducing apoptosis through increasing the DR5 protein level and PARP1 cleavage. LSS-11 dose-dependently reduces STAT3 phosphorylation, downregulates its target genes MDR1 and *MRP1, reduces P-gp* protein expressionwithout affecting P-gp transport function. Lss-11 is a chemosensitizer and shows synergistic anticancer effect with Paclitaxel (HY-B0015). Lss-11 can be used for the research of paclitaxel-resistant lung cancer .

HY-129037

BCRP-IN-1	BCRP	Cancer
BCRP-IN-1 (compound 48) is a potent inhibitor of breast cancer resistance protein (BCRP), with IC₅₀s of 2.92 μM and 2.46 μM in Hoechst 33342 assay and Pheophorbide A assay, respectively .

HY-17013D

Dofequidar sesquifumarate MS-209 sesquifumarate	P-glycoprotein	Cancer
Dofequidar (MS-209) sesquifumarate is an orally active quinoline compoundthat blocks P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MDR-1). Dofequidar sesquifumarate has highly potent reversing effect on multidrug-resistant tumor cells. Dofequidar sesquifumarate competitively inhibits ABCB1/P-gp, ABCC1/MRP-1, blocks the efflux of chemotherapeutic agents, increases the drug concentration in cancer cells, and enhances the chemotherapeutic effect .

HY-17013AR

Dofequidar fumarate (Standard) MS-209 (Standard)	P-glycoprotein Reference Standards	Cancer
Dofequidar (fumarate) (Standard) is the analytical standard of Dofequidar (fumarate). This product is intended for research and analytical applications. Dofequidar fumarate (MS-209) is an orally active quinoline compoundthat blocks P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MDR-1). Dofequidar fumarate has highly potent reversing effect on multidrug-resistant tumor cells. Dofequidar fumarate competitively inhibits ABCB1/P-gp, ABCC1/MRP-1, blocks the efflux of chemotherapeutic agents, increases the drug concentration in cancer cells, and enhances the chemotherapeutic effect .

Cat. No.	Product Name	Category	Target	Chemical Structure